REPORTS

Let’s Pullulate and Expand Your Business

Diabetic Peripheral Neuropathy Treatment Market - Global Professional Analysis and Forecast to 2026

Oct 18, 2019  |  189 PAGES  |  REPORT CODE: CMM216326
  • REPORT SUMMARY
  • TABLE OF CONTENTS
  • INDUSTRY COVERAGE

The worldwide Diabetic Peripheral Neuropathy Treatment market was valued at XX.0 Million US$ in 2018 and is projected to reach XX.0 Million US$ by 2026, at a CAGR (Compound Annual Growth Rate) of 5.1% during the forecast period.

This report presents the market size and development trends by detailing the Diabetic Peripheral Neuropathy Treatment market revenue, market share and growth rate from 2015-2026, and it gives a thorough analysis by various product types, applications, regions, and main participants. The market conditions (2015-2019), corporate competition pattern, corporate SWOT analysis are elaborated, and other qualitative analyses like market dynamics, market penetration, market business environment analyses, the regional regulatory scenario in the Diabetic Peripheral Neuropathy Treatment market will be shown in this report. In short, this report will comprehensively reveal the characteristics of Diabetic Peripheral Neuropathy Treatment industry and will help you to build a panoramic view of the industrial development.

Diabetic Peripheral Neuropathy Treatment Market, By Type:

  • Antimunocel

  • ASP-8477

  • BNV-222

  • Capsaicin

  • CBX-129801

  • Others

Diabetic Peripheral Neuropathy Treatment Market, By Application:

  • Hospital

  • Clinic

  • Others

Some of the leading players are as follows:

  • Reata Pharmaceuticals Inc

  • Grunenthal GmbH

  • Medifron DBT Co Ltd

  • Novaremed Ltd

  • KPI Therapeutics Inc

  • Mitsubishi Tanabe Pharma Corp

  • Celgene Corp

  • Achelios Therapeutics Inc

  • Commence Bio Inc

  • ViroMed Co Ltd

  • Relief Therapeutics Holding AG

  • Immune Pharmaceuticals Inc

Geographically, Major regions are analyzed in details are as follows:

  • North America

  • Europe

  • Asia Pacific

  • Latin America

  • Middle East & Africa

Table of Contents

1 Methodology and Scope

  • 1.1 Market Segmentation & Scope

    • 1.1.1 Technology Type

    • 1.1.2 Product

    • 1.1.3 Application

    • 1.1.4 Regional scope

    • 1.1.5 Estimates and forecast timeline

  • 1.2 Research Methodology

  • 1.3 Information Procurement

    • 1.3.1 Purchased database

    • 1.3.2 Internal database

    • 1.3.3 Secondary sources

    • 1.3.4 Primary research

    • 1.3.5 Details of primary research

  • 1.4 Information or Data Analysis

    • 1.4.1 Data analysis models

  • 1.5 Market Formulation & Validation

  • 1.6 Model Details

    • 1.6.1 Commodity flow analysis

    • 1.6.2 Volume price analysis

  • 1.7 List of Secondary Sources

  • 1.8 List of Abbreviations

2 Executive Summary

  • 2.1 Market Outlook

  • 2.2 Segment Outlook

3 Market Variables, Trends, & Scope

  • 3.1 Market Lineage Outlook

  • 3.1.1 Parent market outlook

    • 3.1.2 Ancillary market outlook

  • 3.2 Market Segmentation

    • 3.2.1 Analysis

  • 3.3 Market Dynamics

    • 3.3.1 Market driver analysis

    • 3.3.2 Market restraint analysis

    • 3.3.3 Industry opportunities

  • 3.4 Penetration & Growth Prospect Mapping

    • 3.4.1 Penetration & growth prospect mapping analysis

  • 3.5 Business Environment Analysis Tools

    • 3.5.1 Porter's five forces analysis

    • 3.5.2 PESTLE analysis

    • 3.5.3 Major deals & strategic alliances analysis

4 Diabetic Peripheral Neuropathy Treatment Market: Technology Type Analysis

  • 4.1 Diabetic Peripheral Neuropathy Treatment Technology Type Market Share Analysis, 2018 & 2026

  • 4.2 Diabetic Peripheral Neuropathy Treatment Technology Type Market: Segment Dashboard

  • 4.3 Market Size & Forecasts and Trend Analyses, 2015 to 2026 for the Technology Type Segment

    • 4.3.1 Antimunocel

    • 4.3.2 ASP-8477

    • 4.3.3 BNV-222

    • 4.3.4 Capsaicin

    • 4.3.5 CBX-129801

    • 4.3.6 Others

5 Diabetic Peripheral Neuropathy Treatment Market: Product Analysis

  • 5.1 Diabetic Peripheral Neuropathy Treatment Product Market Share Analysis, 2018 & 2026

  • 5.2 Diabetic Peripheral Neuropathy Treatment Product Market: Segment Dashboard

  • 5.3 Market Size & Forecasts and Trend Analyses, 2015 to 2026 for the Product Segment

6 Diabetic Peripheral Neuropathy Treatment Market: Application Analysis

  • 6.1 Diabetic Peripheral Neuropathy Treatment Application Market Share Analysis, 2018 & 2026

  • 6.2 Diabetic Peripheral Neuropathy Treatment Application Market: Segment Dashboard

  • 6.3 Market Size & Forecasts and Trend Analyses, 2015 to 2026 for the Application Segment

    • 6.3.1 Hospital

    • 6.3.2 Clinic

    • 6.3.3 Others

7 Diabetic Peripheral Neuropathy Treatment Market: Regional Analysis

  • 7.1 Diabetic Peripheral Neuropathy Treatment Regional Market Share Analysis, 2018 & 2026

  • 7.2 Diabetic Peripheral Neuropathy Treatment Regional Market: Segment Dashboard

  • 7.3 Regional Market Snapshot (Market Size, CAGR, Top Countries)

  • 7.4 List of Players at Regional Level

    • 7.4.1 North America

    • 7.4.2 Europe

    • 7.4.3 Asia Pacific

  • 7.5 SWOT Analysis, by Factor (Political & Legal, Economic and Technological)

    • 7.5.1 North America

    • 7.5.2 Europe

    • 7.5.3 Asia Pacific

    • 7.5.4 Latin America

    • 7.5.5 MEA

  • 7.6 Market Size & Forecasts, and Trend Analysis, 2015 to 2026

    • 7.6.1 North America

    • 7.6.2 Europe

    • 7.6.3 Asia Pacific

    • 7.6.4 Latin America

    • 7.6.5 Middle East & Africa

8 Competitive Analysis

  • 8.1 Recent Developments & Impact Analysis, by Key Market Participants

  • 8.2 Strategic Framework/Competition Categorization (Key innovators, Market leaders, Emerging players)

  • 8.3 Vendor Landscape

    • 8.3.1 Company market position analysis (Geographic presence, service portfolio, strategic initiatives)

9 Company Profiles

  • 9.1 Reata Pharmaceuticals Inc

    • 9.1.1 Reata Pharmaceuticals Inc Company overview

    • 9.1.2 Financial performance

    • 9.1.3 Product benchmarking

    • 9.1.4 Strategic initiatives

    • 9.1.5 SWOT analysis

  • 9.2 Grunenthal GmbH

    • 9.2.1 Grunenthal GmbH Company overview

    • 9.2.2 Financial performance

    • 9.2.3 Product benchmarking

    • 9.2.4 Strategic initiatives

    • 9.2.5 SWOT analysis

  • 9.3 Medifron DBT Co Ltd

    • 9.3.1 Medifron DBT Co Ltd Company overview

    • 9.3.2 Financial performance

    • 9.3.3 Product benchmarking

    • 9.3.4 Strategic initiatives

    • 9.3.5 SWOT analysis

  • 9.4 Novaremed Ltd

    • 9.4.1 Novaremed Ltd Company overview

    • 9.4.2 Financial performance

    • 9.4.3 Product benchmarking

    • 9.4.4 Strategic initiatives

    • 9.4.5 SWOT analysis

  • 9.5 KPI Therapeutics Inc

    • 9.5.1 KPI Therapeutics Inc Company overview

    • 9.5.2 Financial performance

    • 9.5.3 Product benchmarking

    • 9.5.4 Strategic initiatives

    • 9.5.5 SWOT analysis

  • 9.6 Mitsubishi Tanabe Pharma Corp

    • 9.6.1 Mitsubishi Tanabe Pharma Corp Company overview

    • 9.6.2 Financial performance

    • 9.6.3 Product benchmarking

    • 9.6.4 Strategic initiatives

    • 9.6.5 SWOT analysis

  • 9.7 Celgene Corp

    • 9.7.1 Celgene Corp Company overview

    • 9.7.2 Financial performance

    • 9.7.3 Product benchmarking

    • 9.7.4 Strategic initiatives

    • 9.7.5 SWOT analysis

  • 9.8 Achelios Therapeutics Inc

    • 9.8.1 Achelios Therapeutics Inc Company overview

    • 9.8.2 Financial performance

    • 9.8.3 Product benchmarking

    • 9.8.4 Strategic initiatives

    • 9.8.5 SWOT analysis

  • 9.9 Commence Bio Inc

    • 9.9.1 Commence Bio Inc Company overview

    • 9.9.2 Financial performance

    • 9.9.3 Product benchmarking

    • 9.9.4 Strategic initiatives

    • 9.9.5 SWOT analysis

  • 9.10 ViroMed Co Ltd

    • 9.10.1 ViroMed Co Ltd Company overview

    • 9.10.2 Financial performance

    • 9.10.3 Product benchmarking

    • 9.10.4 Strategic initiatives

    • 9.10.5 SWOT analysis

  • 9.11 Relief Therapeutics Holding AG

    • 9.11.1 Relief Therapeutics Holding AG Company overview

    • 9.11.2 Financial performance

    • 9.11.3 Product benchmarking

    • 9.11.4 Strategic initiatives

    • 9.11.5 SWOT analysis

  • 9.12 Immune Pharmaceuticals Inc

    • 9.12.1 Immune Pharmaceuticals Inc Company overview

    • 9.12.2 Financial performance

    • 9.12.3 Product benchmarking

    • 9.12.4 Strategic initiatives

    • 9.12.5 SWOT analysis

 

The List of Tables and Figures (Totals 93 Figures and 146 Tables)

  • Figure Antimunocel Diabetic Peripheral Neuropathy Treatment market, 2015 - 2026 (USD Million)

  • Figure ASP-8477 Diabetic Peripheral Neuropathy Treatment market, 2015 - 2026 (USD Million)

  • Figure BNV-222 Diabetic Peripheral Neuropathy Treatment market, 2015 - 2026 (USD Million)

  • Figure Capsaicin Diabetic Peripheral Neuropathy Treatment market, 2015 - 2026 (USD Million)

  • Figure CBX-129801 Diabetic Peripheral Neuropathy Treatment market, 2015 - 2026 (USD Million)

  • Figure Others Diabetic Peripheral Neuropathy Treatment market, 2015 - 2026 (USD Million)

  • Figure Hospital market, 2015 - 2026 (USD Million)

  • Figure Clinic market, 2015 - 2026 (USD Million)

  • Figure Others market, 2015 - 2026 (USD Million)

  • Table List of players in North America

  • Table List of players in Europe

  • Table List of players in Asia Pacific

  • Table SWOT analysis

  • Table North America Diabetic Peripheral Neuropathy Treatment market, by country, 2015 - 2026 (USD Million)

  • Table North America Diabetic Peripheral Neuropathy Treatment market, by type, 2015 - 2026 (USD Million)

  • Table North America Diabetic Peripheral Neuropathy Treatment market, by product, 2015 - 2026 (USD Million)

  • Table North America Diabetic Peripheral Neuropathy Treatment market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table U.S. Diabetic Peripheral Neuropathy Treatment market, by type, 2015 - 2026 (USD Million)

  • Table U.S. Diabetic Peripheral Neuropathy Treatment market, by product, 2015 - 2026 (USD Million)

  • Table U.S. Diabetic Peripheral Neuropathy Treatment market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Canada Diabetic Peripheral Neuropathy Treatment market, by type, 2015 - 2026 (USD Million)

  • Table Canada Diabetic Peripheral Neuropathy Treatment market, by product, 2015 - 2026 (USD Million)

  • Table Canada Diabetic Peripheral Neuropathy Treatment market, by application, 2015 - 2026 (USD Million)

  • Table Europe Diabetic Peripheral Neuropathy Treatment market, by country, 2015 - 2026 (USD Million)

  • Table Europe Diabetic Peripheral Neuropathy Treatment market, by type, 2015 - 2026 (USD Million)

  • Table Europe Diabetic Peripheral Neuropathy Treatment market, by product, 2015 - 2026 (USD Million)

  • Table Europe Diabetic Peripheral Neuropathy Treatment market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table U.K. Diabetic Peripheral Neuropathy Treatment market, by type, 2015 - 2026 (USD Million)

  • Table U.K. Diabetic Peripheral Neuropathy Treatment market, by product, 2015 - 2026 (USD Million)

  • Table U.K. Diabetic Peripheral Neuropathy Treatment market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Germany Diabetic Peripheral Neuropathy Treatment market, by type, 2015 - 2026 (USD Million)

  • Table Germany Diabetic Peripheral Neuropathy Treatment market, by product, 2015 - 2026 (USD Million)

  • Table Germany Diabetic Peripheral Neuropathy Treatment market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table France Diabetic Peripheral Neuropathy Treatment market, by type, 2015 - 2026 (USD Million)

  • Table France Diabetic Peripheral Neuropathy Treatment market, by product, 2015 - 2026 (USD Million)

  • Table France Diabetic Peripheral Neuropathy Treatment market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Italy Diabetic Peripheral Neuropathy Treatment market, by type, 2015 - 2026 (USD Million)

  • Table Italy Diabetic Peripheral Neuropathy Treatment market, by product, 2015 - 2026 (USD Million)

  • Table Italy Diabetic Peripheral Neuropathy Treatment market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Spain Diabetic Peripheral Neuropathy Treatment market, by type, 2015 - 2026 (USD Million)

  • Table Spain Diabetic Peripheral Neuropathy Treatment market, by product, 2015 - 2026 (USD Million)

  • Table Spain Diabetic Peripheral Neuropathy Treatment market, by application, 2015 - 2026 (USD Million)

  • Table Asia Pacific Diabetic Peripheral Neuropathy Treatment market, by country, 2015 - 2026 (USD Million)

  • Table Asia Pacific Diabetic Peripheral Neuropathy Treatment market, by type, 2015 - 2026 (USD Million)

  • Table Asia Pacific Diabetic Peripheral Neuropathy Treatment market, by product, 2015 - 2026 (USD Million)

  • Table Asia Pacific Diabetic Peripheral Neuropathy Treatment market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table China Diabetic Peripheral Neuropathy Treatment market, by type, 2015 - 2026 (USD Million)

  • Table China Diabetic Peripheral Neuropathy Treatment market, by product, 2015 - 2026 (USD Million)

  • Table China Diabetic Peripheral Neuropathy Treatment market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Japan Diabetic Peripheral Neuropathy Treatment market, by type, 2015 - 2026 (USD Million)

  • Table Japan Diabetic Peripheral Neuropathy Treatment market, by product, 2015 - 2026 (USD Million)

  • Table Japan Diabetic Peripheral Neuropathy Treatment market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table India Diabetic Peripheral Neuropathy Treatment market, by type, 2015 - 2026 (USD Million)

  • Table India Diabetic Peripheral Neuropathy Treatment market, by product, 2015 - 2026 (USD Million)

  • Table India Diabetic Peripheral Neuropathy Treatment market, by application, 2015 - 2026 (USD Million)

  • Table Latin America Diabetic Peripheral Neuropathy Treatment market, by country, 2015 - 2026 (USD Million)

  • Table Latin America Diabetic Peripheral Neuropathy Treatment market, by type, 2015 - 2026 (USD Million)

  • Table Latin America Diabetic Peripheral Neuropathy Treatment market, by product, 2015 - 2026 (USD Million)

  • Table Latin America Diabetic Peripheral Neuropathy Treatment market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Brazil Diabetic Peripheral Neuropathy Treatment market, by type, 2015 - 2026 (USD Million)

  • Table Brazil Diabetic Peripheral Neuropathy Treatment market, by product, 2015 - 2026 (USD Million)

  • Table Brazil Diabetic Peripheral Neuropathy Treatment market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Mexico Diabetic Peripheral Neuropathy Treatment market, by type, 2015 - 2026 (USD Million)

  • Table Mexico Diabetic Peripheral Neuropathy Treatment market, by product, 2015 - 2026 (USD Million)

  • Table Mexico Diabetic Peripheral Neuropathy Treatment market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Argentina Diabetic Peripheral Neuropathy Treatment market, by type, 2015 - 2026 (USD Million)

  • Table Argentina Diabetic Peripheral Neuropathy Treatment market, by product, 2015 - 2026 (USD Million)

  • Table Argentina Diabetic Peripheral Neuropathy Treatment market, by application, 2015 - 2026 (USD Million)

  • Table MEA Diabetic Peripheral Neuropathy Treatment market, by country, 2015 - 2026 (USD Million)

  • Table MEA Diabetic Peripheral Neuropathy Treatment market, by type, 2015 - 2026 (USD Million)

  • Table MEA Diabetic Peripheral Neuropathy Treatment market, by product, 2015 - 2026 (USD Million)

  • Table MEA Diabetic Peripheral Neuropathy Treatment market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table South Africa Diabetic Peripheral Neuropathy Treatment market, by type, 2015 - 2026 (USD Million)

  • Table South Africa Diabetic Peripheral Neuropathy Treatment market, by product, 2015 - 2026 (USD Million)

  • Table South Africa Diabetic Peripheral Neuropathy Treatment market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Nigeria Diabetic Peripheral Neuropathy Treatment market, by type, 2015 - 2026 (USD Million)

  • Table Nigeria Diabetic Peripheral Neuropathy Treatment market, by product, 2015 - 2026 (USD Million)

  • Table Nigeria Diabetic Peripheral Neuropathy Treatment market, by application, 2015 - 2026 (USD Million)

  • Table Recent Developments & Impact Analysis, by Key Market Participants

  • Table Recent Developments & Impact Analysis, by Key Market Participants

  • Table Company market position analysis

  • Table Company Profiles

  • Table Reata Pharmaceuticals Inc Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Grunenthal GmbH Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Medifron DBT Co Ltd Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Novaremed Ltd Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table KPI Therapeutics Inc Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Mitsubishi Tanabe Pharma Corp Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Celgene Corp Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Achelios Therapeutics Inc Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Commence Bio Inc Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table ViroMed Co Ltd Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Relief Therapeutics Holding AG Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Immune Pharmaceuticals Inc Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

Report Purchase

reports
$4840
$9680
BUY NOWClick MeBUY NOW
top